Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Baxter
McKinsey
AstraZeneca
Johnson and Johnson
Harvard Business School

Last Updated: October 18, 2019

DrugPatentWatch Database Preview

Details for Patent: 7,419,973

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 7,419,973 protect, and when does it expire?

Patent 7,419,973 protects TEFLARO and is included in one NDA.

This patent has seventeen patent family members in thirteen countries.

Summary for Patent: 7,419,973
Title:Phosphonocephem compound
Abstract:A cephem compound (particularly its crystal) represented by the formula [I], wherein X is CH.sub.3COOH, CH.sub.3CH.sub.2COOH or CH.sub.3CN, and n is 0 to 5, is useful as an antibacterial agent (particularly anti-MRSA agent) and shows superior quality such as high solid stability, possible long-term stable preservation and the like. ##STR00001##
Inventor(s): Ishikawa; Tomoyasu (Shiga, JP), Hashiguchi; Shohei (Osaka, JP), Iizawa; Yuji (Kyoto, JP)
Assignee: Takeda Pharmaceutical Company Limited (Osaka, JP)
Application Number:11/063,715
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,419,973
Patent Claim Types:
see list of patent claims
Composition; Compound; Formulation;

Drugs Protected by US Patent 7,419,973

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Allergan Sales Llc TEFLARO ceftaroline fosamil POWDER;INTRAVENOUS 200327-001 Oct 29, 2010 RX Yes No   Start Trial   Start Trial Y   Start Trial
Allergan Sales Llc TEFLARO ceftaroline fosamil POWDER;INTRAVENOUS 200327-002 Oct 29, 2010 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 7,419,973

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan2000-247966Aug 10, 2000
Japan2000-354959Nov 21, 2000

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Colorcon
Baxter
Johnson and Johnson
Dow
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.